TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03789552: Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

Sponsor: Tasly Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 765 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT03789552 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03789552 Rescue Dossier →